|
1
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO Classification of Tumours of the
BreastInternational Agency for Research on Cancer. Lyon: 2012,
View Article : Google Scholar
|
|
2
|
Clarke CA, Keegan TH, Yang J, Press DJ,
Kurian AW, Patel AH and Lacey JV Jr: Age-specific incidence of
breast cancer subtypes: Understanding the black-white crossover. J
Natl Cancer Inst. 104:1094–1101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurian AW, Fish K, Shema SJ and Clarke CA:
Lifetime risks of specific breast cancer subtypes among women in
four racial/ethnic groups. Breast Cancer Res. 12:R992010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olsson HL, Ingvar C and Bladström A:
Hormone replacement therapy containing progestins and given
continuously increases breast carcinoma risk in Sweden. Cancer.
97:1387–1392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clavel-Chapelon F and Hill C: Hormone
replacement therapy in menopause and risk of breast cancer. Presse
Med. 29:1688–1693. 2000.(In French). PubMed/NCBI
|
|
6
|
Bae JM and Kim EH: Hormone replacement
therapy and risk of breast cancer in Korean women: A quantitative
systematic review. J Prev Med Public Health. 48:225–230. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Predná L, Habánová M, Sláviková E and Wyka
J: Hormonal contraceptives and hormone replacement therapy as a
possible factor of breast cancer. Rocz Panstw Zakl Hig. 66:269–274.
2015.PubMed/NCBI
|
|
8
|
Orecchioni S, Reggiani F, Talarico G and
Bertolini F: Mechanisms of obesity in the development of breast
cancer. Discov Med. 20:121–128. 2015.PubMed/NCBI
|
|
9
|
Bertolini F: Adipose tissue and breast
cancer progression: A link between metabolism and cancer. Breast.
22:(Suppl 2). S48–S49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bertolini F, Petit JY and Kolonin MG: Stem
cells from adipose tissue and breast cancer: Hype, risks and hope.
Br J Cancer. 112:419–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jayasekara H, MacInnis RJ, Room R and
English DR: Long-term alcohol consumption and breast, upper
aero-digestive tract and colorectal cancer risk: A systematic
review and meta-Analysis. Alcohol Alcohol. 51:315–330. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van den Broek AJ, Schmidt MK, van't Veer
LJ, Tollenaar RA and van Leeuwen FE: Worse breast cancer prognosis
of BRCA1/BRCA2 mutation carriers: What's the evidence? A systematic
review with meta-analysis. PLoS One. 10:e01201892015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Llort G, Peris M and Blanco I: Hereditary
breast and ovarian cancer: Primary and secondary prevention for
BRCA1 and BRCA2 mutation carriers. Med Clin (Barc). 128:468–476.
2007.(In Spanish). View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calderon-Margalit R and Paltiel O:
Prevention of breast cancer in women who carry BRCA1 or BRCA2
mutations: A critical review of the literature. Int J Cancer.
112:357–364. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Olsen CM, Wilson LF, Nagle CM, Kendall BJ,
Bain CJ, Pandeya N, Webb PM and Whiteman DC: Cancers in Australia
in 2010 attributable to insufficient physical activity. Aust N Z J
Public Health. 39:458–463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Drooger JC, Hooning MJ, Seynaeve CM,
Baaijens MH, Obdeijn IM, Sleijfer S and Jager A: Diagnostic and
therapeutic ionizing radiation and the risk of a first and second
primary breast cancer, with special attention for BRCA1 and BRCA2
mutation carriers: A critical review of the literature. Cancer
Treat Rev. 41:187–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang J, Fernandez-Garcia I, Vijayakumar S,
Martinez-Ruis H, Illa-Bochaca I, Nguyen DH, Mao JH, Costes SV and
Barcellos-Hoff MH: Irradiation of juvenile, but not adult, mammary
gland increases stem cell self-renewal and estrogen receptor
negative tumors. Stem Cells. 32:649–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clemons M, Loijens L and Goss P: Breast
cancer risk following irradiation for Hodgkin's disease. Cancer
Treat Rev. 26:291–302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haffty BG: Radiation therapy and the risk
of contralateral breast cancer. Int J Radiat Oncol Biol Phys.
56:920–921. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kato I, Tominaga S and Suzuki T: Factors
related to late menopause and early menarche as risk factors for
breast cancer. Jpn J Cancer Res. 79:165–172. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Altekruse SF, Kosary CL, Krapcho M, Neyman
N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, et
al: SEER Cancer Statistics Review, 1975–2007. Bethesda, MD:
National Cancer Institute; 2010
|
|
22
|
Diab SG, Elledge RM and Clark GM: Tumor
characteristics and clinical outcome of elderly women with breast
cancer. J Natl Cancer Inst. 92:550–556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jenkins EO, Deal AM, Anders CK, Prat A,
Perou CM, Carey LA and Muss HB: Age-specific changes in intrinsic
breast cancer subtypes: A focus on older women. Oncologist.
19:1076–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walter LC and Covinsky KE: Cancer
screening in elderly patients: A framework for individualized
decision making. JAMA. 285:2750–2756. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benz CC: Impact of aging on the biology of
breast cancer. Crit Rev Oncol Hematol. 66:65–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ihemelandu CU, Leffall LD Jr, Dewitty RL,
Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L and Frederick
WA: Molecular breast cancer subtypes in premenopausal and
postmenopausal African-American women: Age-specific prevalence and
survival. J Surg Res. 143:109–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eppenberger-Castori S, Moore DH Jr, Thor
AD, Edgerton SM, Kueng W, Eppenberger U and Benz CC: Age-associated
biomarker profiles of human breast cancer. Int J Biochem Cell Biol.
34:1318–1330. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quong J, Eppenberger-Castori S, Moore D
III, Scott GK, Birrer MJ, Kueng W, Eppenberger U and Benz CC:
Age-dependent changes in breast cancer hormone receptors and
oxidant stress markers. Breast Cancer Res Treat. 76:221–236. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Camerlingo R, Ferraro GA, De Francesco F,
Romano M, Nicoletti G, Di Bonito M, Rinaldo M, D'Andrea F and
Pirozzi G: The role of CD44+/CD24-/low biomarker for screening,
diagnosis and monitoring of breast cancer. Oncol Rep. 31:1127–1132.
2014.PubMed/NCBI
|
|
30
|
Gudadze M, Kankava Q, Mariamidze A and
Burkadze G: Features of CD44+/CD24-low phenotypic cell distribution
in relation to predictive markers and molecular subtypes of
invasive ductal carcinoma of the breast. Georgian Med News.
228:81–87. 2014.
|
|
31
|
Eroles P, Bosch A, Pérez-Fidalgo JA and
Lluch A: Molecular biology in breast cancer: Intrinsic subtypes and
signaling pathways. Cancer Treat Rev. 38:698–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morrison DH, Rahardja D, King E, Peng Y
and Sarode VR: Tumour biomarker expression relative to age and
molecular subtypes of invasive breast cancer. Br J Cancer.
107:382–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park S, Koo JS, Kim MS, Park HS, Lee JS,
Lee JS, Kim SI and Park BW: Characteristics and outcomes according
to molecular subtypes of breast cancer as classified by a panel of
four biomarkers using immunohistochemistry. Breast. 21:50–57. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rakha EA and Ellis IO:
Triple-negative/basal-like breast cancer: Review. Pathology.
41:40–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Santos C, Sanz-Pamplona R, Nadal E,
Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J and
Salazar R: Intrinsic cancer subtypes-next steps into personalized
medicine. Cell Oncol (Dordr). 38:3–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
LSI Her-2/neu (Orange)/CEP 17 (Green)
Users guide. Intellmed s.r.o.Olomouc; Czech Republic: 2006
|
|
40
|
Anders CK, Hsu DS, Broadwater G, Acharya
CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, et
al: Young age at diagnosis correlates with worse prognosis and
defines a subset of breast cancers with shared patterns of gene
expression. J Clin Oncol. 26:3324–3330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
de Kruijf EM, Bastiaannet E, Rubertá F, de
Craen AJ, Kuppen PJ, Smit VT, van de Velde CJ and Liefers GJ:
Comparison of frequencies and prognostic effect of molecular
subtypes between young and elderly breast cancer patients. Mol
Oncol. 8:1014–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jenkins EO, Deal AM, Anders CK, Prat A,
Perou CM, Carey LA and Muss HB: Age-specific changes in intrinsic
breast cancer subtypes: A focus on older women. Oncologist.
19:1076–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Prat A, Carey LA, Adamo B, Vidal M,
Tabernero J, Cortés J, Parker JS, Perou CM and Baselga J: Molecular
features and survival outcomes of the intrinsic subtypes within
HER2-positive breast cancer. J Natl Cancer Inst. 106:dju1522014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park YH, Lee SJ, Jung HA, Kim SM, Kim MJ,
Kil WH, Lee JE, Nam SJ, Ahn JS and Im YH: Prevalence and clinical
outcomes of young breast cancer (YBC) patients according to
intrinsic breast cancer subtypes: Single institutional experience
in Korea. Breast. 24:213–217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Merino D, Lok SW, Visvader JE and Lindeman
GJ: Targeting BCL-2 to enhance vulnerability to therapy in estrogen
receptor-positive breast cancer. Oncogene. 35:1877–1887. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dawson SJ, Makretsov N, Blows FM, Driver
KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG,
McLean CA, et al: BCL2 in breast cancer: A favourable prognostic
marker across molecular subtypes and independent of adjuvant
therapy received. Br J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Choi JE, Kang SH, Lee SJ and Bae YK:
Prognostic significance of Bcl-2 expression in non-basal triple
negative breast cancer patients treated with anthracycline-based
chemotherapy. Tumour Biol. 35:12255–12263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bouchalova K, Kharaishvili G, Bouchal J,
Vrbkova J, Megova M and Hlobilkova A: Triple negative breast
cancer-BCL2 in prognosis and prediction. Review. Curr Drug Targets.
15:1166–1175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bouchalova K, Svoboda K, Kharaishvili G,
Vrbkova J, Bouchal J, Trojanec R, Koudelakova V, Radova L, Cwiertka
K, Hajduch M and Kolar Z: BCL2 is an independent predictor of
outcome in basal-like triple-negative breast cancers treated with
adjuvant anthracycline-based chemotherapy. Tumour Biol.
36:4243–4252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Perillo B, Sasso A, Abbondanza C and
Palumbo G: 17beta-estradiol inhibits apoptosis in MMCF-7 cells,
including bcl-2 expression via two estrogen-responsive elements
present in the coding sequence. Mol Cell Biol. 20:2890–2901. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Certo M, Del Gaizo Moore V, Nishino M, Wei
G, Korsmeyer S, Armstrong SA and Letai A: Mitochondria primed by
death signals determine cellular addiction to antiapoptotic BCL-2
family members. Cancer Cell. 9:351–365. 2015. View Article : Google Scholar
|
|
52
|
Honma N, Horii R, Ito Y, Saji S, Younes M,
Iwase T and Akiyama F: Differences in clinical importance of Bcl-2
in breast cancer according to hormone receptor status or adjuvant
endocrine therapy. BMC Cancer. 15:6982015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Seong MK, Lee JY, Byeon J, Sohn YJ, Seol
H, Lee JK, Kim EK, Kim HA and Noh WC: Bcl-2 is a highly significant
prognostic marker of hormone-receptor-positive, human epidermal
growth factor receptor-2-negative breast cancer. Breast Cancer Res
Treat. 150:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
